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The development of BPD in premature infants is a multifactorial process that involves both prenatal and postnatal exposures. Changes leading to BPD begin in utero and are affected by antenatal steroids, gestational age, birthweight, gender, maternal inflammation, and maternal BMI. [1] [2] [3] BPD develops over the infant's first several weeks, influenced by mechanical ventilation, excessive oxygen exposure, postnatal infections, nutrition and growth, and certain medications. 2, 4 These factors and others, share the common connection of propagation of pulmonary inflammation in the fetus and newborn.
The pulmonary tissue of the human fetus during the canalicular stage of lung development (17-27 weeks' gestation) has limited respiratory units capable of gas exchange and surfactant production. 
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Hemodynamically significant patent ductus arteriosus and the development of bronchopulmonary dysplasia
The PDA has also long been recognized as a risk factor for devel- It is estimated that BPD risk increases by 70% for each additional week of exposure to an hsPDA. 10 The canalicular stage of lung development is also remarkable for a relatively underdeveloped pulmonary vascular bed. The low cross-sectional area of the vascular system in the fetal lungs helps to maintain high pulmonary vascular resistance and limits blood flow through the lungs to approximately 25% of right ventricular output at 20 weeks postmenstrual age, increasing to 44% by 30 weeks. 12 As the fetus is born, pulmonary vascular resistance begins to drop; this allows the ductus to transition from a rightto-left shunt to a left-to-right shunt. Under these conditions, pulmonary blood flow is greater than right ventricular output, and blood return to the left side of the heart is increased. If pulmonary blood flow exceeds the capacity of the left ventricle, hydrostatic pressure increases in the pulmonary capillary bed, pushing fluid from the vascular space to the interstitial space, and contributing to pulmonary edema.
In the first few days after birth, the neonate may be protected against pulmonary edema by increased lymph flow that quickly clears excess fluid from the lungs. 13 However, if ductal flow increases or lymph drainage is impaired, the capacity of the lymph channels to clear interstitial fluid may be exceeded causing fluid to remain within the interstitial space. Interstitial edema separates the alveolar surface from the surrounding capillary bed, limiting gas exchange by increasing the distance over which gas molecules must diffuse ( Figure 1 ). Ineffective gas exchange results in ventilation perfusion mismatch and hypoxemia, recognized at the bedside as a decline in oxygen saturation. The immediate response is to increase delivery of inspired oxygen, a strategy that may correct hypoxemia in the short term, but leads to the development of simplified alveoli, a hallmark of BPD. 14 The effect of increased oxygen exposure is illustrated in a mouse model (Figure 2 ), demonstrating that alveolar simplification increases with prolonged exposure to higher concentrations of oxygen.
To decrease oxygen exposure, the provider may choose to increase alveolar distending pressure ( Figure 1D ). This strategy can improve gas exchange, but often requires mechanical ventilation, which has also been shown in animal models to induce apoptosis of alveolar cells and leads to impaired angiogenesis within the lung. 15, 16 Furthermore, mechanical ventilation induces an inflammatory cascade in the neonatal lung leading to increased microvascular permeability and increased lung fluid. 17 Such inflammation, coupled with developing fibrosis that impairs lymph drainage, compounds the problem of excessive pulmonary flow and overwhelms the neonate's ability to clear lung fluid. This process can cause PDA-related pulmonary edema several days after birth in a patient who had previously tolerated the left-to-right PDA shunt.
Over time, exposure to excessive pulmonary blood flow alters the development of pulmonary vasculature. A paucity of pulmonary vessels is a pathological feature of BPD. 18 In a preclinical rat model, persistent exposure to elevated blood flow led to an increase in pulmonary vascular resistance and alterations in alveolar structure characteristic of BPD. 19 Similar changes occur in preterm infants with pulmonary hypertension, systemic to pulmonary vascular connections, and pulmonary vein stenosis, all of which may also be related to increased vascular resistance and pulmonary overcirculation. 20 Strategies to avoid mechanical ventilation in premature infants, especially in the first week after birth, have been shown to reduce the incidence of BPD. 21, 22 These strategies, however, seem to have no effect on the diagnosis of PDA. In a trial comparing early synchro- Inconsistency in the diagnosis of hsPDA may obscure the link between a PDA and BPD development. As previously described, the volume of PDA flow is a key factor in determining BPD risk. 9, 10 Assessing PDA flow by echocardiogram, however, is labor-intensive and requires significant skill. Identification of a marker that is both sensitive and specific for hsPDA and less difficult to acquire than echocardiography may solidify the causality between the presence of a PDA and later BPD development. One such marker may be N-terminal probrain natriuretic peptide (NT-proBNP), which is emerging in clinical use for the diagnosis of hsPDA. A recent meta-analysis found NT-proBNP to be a more sensitive, but less specific marker for hsPDA than brain natriuretic peptide, a similar marker of atrial dilatation that has been used as a biomarker for cardiac dysfunction due to PDA. 25 NT-proBNP has been shown to have good correlation with flow patterns on echocardiography that are associated with hemodynamic significance of the PDA.
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Recent work by Rodríguez-Blanco et al 27 suggests that for the prediction of BPD, NT-proBNP may be a superior measure of an hsPDA than echocardiography because increased NT-proBNP levels more accurately predicted the development of BPD than did the detection of an hsPDA by echocardiography alone. This relationship may explain earlier work suggesting NT-proBNP is an independent biomarker of BPD development. 28 Future trials using NT-proBNP to target early hsPDA treatment in neonates on mechanical ventilation may be able to show a reduction in BPD among infants at highest risk. Randomization occurred one week after birth, and there was no difference in BPD between groups.
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On the other hand, a reduction in BPD may be found with aggressive PDA closure in the first few days of life. In a cohort study, 37 These data suggest that closure of a moderate-to-large PDA may reduce the risk of BPD, but only if it is successfully closed within the first week, generally before the onset of clinical signs.
One proposed explanation for the lack of benefit from PDA treatment is that commonly available therapies for PDA may independently increase the risk of BPD, obscuring benefits achieved from reducing PDA exposure. An early small study randomized infants born less than 1500 g to receive three doses of indomethacin or placebo beginning 12 hours after birth and showed the indomethacin group had a reduction in PDA but required longer respiratory support. 38 A possible explanation for this can be found in secondary analysis of the Trial of Indomethacin Prophylaxis in Preterms (TIPP).
In this study, prophylactic indomethacin successfully reduced the incidence of PDA among extremely low birthweight infants. However, infants in the indomethacin group had higher oxygen exposure over the first week and lower urine output over the first three days. 39 Prostaglandin E2 (PGE2) plays a major role in regulating urine output by binding to prostaglandin receptors within the nephron; and COX-2 inhibitors such as indomethacin and ibuprofen reduce urine output by blocking PGE2 production. 40, 41 Lower urine output associated with indomethacin treatment in the TIPP trial may have increased intravascular volume and worsened pulmonary congestion.
The increased need for oxygen seems to be independent of fluid balance, and while the effect has also been reported by other studies, the mechanism remains unclear. 39 Surgical ligation of the PDA also may increase the risk of developing BPD. As noted in preterm baboon models, animals that underwent surgical ligation at 6 and 7 days after birth had none of the beneficial biochemical changes associated with pharmacological treatment. There were no significant differences in pulmonary mechanics or histology after 14 days. However, they noted a significant increase in expression of COX-2, TNF-α, and CD14, genes involved with pulmonary inflammation, as well as a decrease in sodium channel expression. 42, 43 These findings support the hypothesis that inflammation resulting from surgical ligation is responsible for blunting the clearance of pulmonary fluid and obscuring any benefit from closure of the PDA.
Human data also suggest increased inflammation related to surgical ligation may increase the risk for adverse pulmonary outcomes.
In a large population-based Finish trial, both medical and surgical treatments were associated with the development of severe BPD. 44 Surgical ligation was also associated an increased risk of necrotizing enterocolitis and intraventricular hemorrhage-both diagnoses associated with increased inflammation. These morbidities are increased despite surgical ligation having a low associated mortality in extremely low birthweight newborns and promoting more rapid termination of mechanical ventilation. 45 In contrast, a recent study of 308 infants from tertiary centers in Canada was unable to show that surgical ligation was associated with BPD. However, post-ligation cardiac syndrome, a recognized serious complication of surgical closure, is strongly associated with more severe BPD. 46 Recognition of the risks associated with surgical ligation and other improvements in neonatal care may be related to the decline in the number of surgical ligations performed in the United States over the last several decades. 47 It remains to be seen if alternatives to surgical closure such as percutaneous closure will be associated with improvement in rates of chronic lung disease.
| CON CLUS ION
Epidemiological studies demonstrate a strong association between the presence of a PDA and the development of BPD. A causal relationship has yet to be proven, and trials investigating either pharmacological or surgical treatment of the PDA have generally failed to prevent the development of BPD. It may be that PDA treatment is beneficial only in select patients with extreme prematurity, high ductal flow rates, and mechanical ventilation in the first week after birth. However, current available therapies may independently increase the risk of BPD in this high-risk population. Future trials may be able to clarify this conundrum by better diagnosing hsPDA, standardizing "conservative" therapies, and considering the role of novel therapies.
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